Biocon Secures US FDA Approval for Liraglutide Injection to Tap Growing GLP-1 Market
Biocon Receives US FDA Nod for Complex Liraglutide Formulation
Biocon Ltd announced on Tuesday that it has received approval from the US Food and Drug Administration for its complex formulation, Liraglutide...
biocon ltd
bse
drug-device combination
european union
fda approval
glp-1 receptor agonists
glucagon-like peptide-1
liraglutide
metabolic disorders
obesity treatment
pharmaceutical formulation
prefilled pens
type 2 diabetes
united states food and drug administration
weight management
